Demand for bartonellosis therapeutics will increase through 2036, with antibiotics at 72.6% of the drug class segment in 2026. Oral administration leads with a 66.8% share. The market was valued at USD 1.5 billion in 2025, reaching USD 1.7 billion by 2026-end and USD 5.1 billion by 2036.